Evista and Nephrogenic anaemia - a phase IV clinical study of FDA data

Summary:

Nephrogenic anaemia is reported as a side effect among people who take Evista (raloxifene hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Nexium, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Nephrogenic anaemia when taking Evista. It is created by eHealthMe based on reports of 25,442 people who have side effects when taking Evista from the FDA, and is updated regularly.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

What is Nephrogenic anaemia?

Nephrogenic anaemia (anaemia due to kidney disease) is found to be associated with 878 drugs and 497 conditions by eHealthMe. Check the latest studies of Nephrogenic anaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

25,442 people reported to have side effects when taking Evista.
Among them, 30 people (0.12%) have Nephrogenic anaemia.

Among these 30 people:

How long have people been on Evista when they have Nephrogenic anaemia? *

What is the gender of people who have Nephrogenic anaemia when taking Evista? *

female: 96.55 %
male: 3.45 %

What is the age of people who have Nephrogenic anaemia when taking Evista? *

What are other drugs people take besides Evista? *

What are other side effects people have besides Nephrogenic anaemia? *

Chronic Kidney Disease: 20 people, 66.67%
Acute Kidney Failure: 17 people, 56.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 33.33%
Pain: 8 people, 26.67%
Renal Disorder (kidney disease): 8 people, 26.67%
Rickets (softening of bones): 8 people, 26.67%
Anaemia (lack of blood): 8 people, 26.67%
Sinus Congestion (blockage of sinus): 7 people, 23.33%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 7 people, 23.33%
Glaucoma (increased fluid pressure in the eye with vision loss): 7 people, 23.33%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 15 people, 50.00%
High Blood Cholesterol: 13 people, 43.33%
Infection: 13 people, 43.33%
Pain: 13 people, 43.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 4 people, 13.33%
Cardiac Disorder: 4 people, 13.33%
High Blood Pressure: 4 people, 13.33%
Depression: 4 people, 13.33%
Dizziness: 3 people, 10.00%
Gout (uric acid crystals building up in the body): 3 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Evista and have Nephrogenic anaemia?

- Check whether Nephrogenic anaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Evista:

Evista (25,891 reports)

Browse all side effects of Evista:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic anaemia:

Nephrogenic anaemia (878 drugs)

Browse all the conditions that are associated with Nephrogenic anaemia:

Nephrogenic anaemia (497 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride (the active ingredients of Evista) and Evista (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.